Clinical Trials
7 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT03162627 2026-04-15
Selumetinib and Olaparib in Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT00780676 2020-09-03
Personalized Treatment Selection for Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01160718 2019-05-15
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
Swiss Cancer Institute
Phase 2 Completed
NCT01313039 2017-02-07
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
University of Miami
Phase EARLY_PHASE1 Completed